Earth and Atmospheric Sciences Professor Jennifer Glass comments on a paper recently published in Science that details “photochemodenitrification,” a nitrous oxide production pathway through which sunlight induces substantial and consistent nitrous oxide formation under oxic abiotic conditions in fresh and marine surface waters. 

“I think it’s a beautiful [study],’ says Glass, noting that researchers have previously shown similar light-driven processes in atmospheric aerosols, but never in aquatic environments. “As we’ve been sequencing more and more genomes in the environment a lot of us have moved really into that -omics space, looking for key markers for genes … This just goes to show that sometimes it’s not biological,” she says. “You have to think outside the box and consider all the chemistry that can be happening, not just the enzymes.”

Nga Lee "Sally" Ng, a professor in the School of Earth and Atmospheric Sciences and the School of Chemical and Biomolecular Engineering, leads the U.S. National Science Foundation-supported Atmospheric Science and Chemistry mEasurement NeTwork (ASCENT), which includes 12 air quality measurement sites nationwide. Each site has state-of-the-art instruments that help us understand aerosols, or tiny particles in the atmosphere. The network is constantly analyzing the chemical constituents of aerosols with a diameter smaller than 2.5 micrometers, referred to as PM2.5, which contribute to more than 90% of the adverse health impacts associated with air pollution.

"We provide ASCENT data to the public in real time so that people know what's in the air we're breathing," Ng said.

Four million Americans suffer from glaucoma, an incurable eye disease that slowly degrades peripheral vision and eventually leads to blindness. A new treatment could potentially stop this degradation and possibly save people’s vision before it’s too late.

Raquel Lieberman, a professor in the School of Chemistry and Biochemistry and the Parker H. Petit Institute for Bioengineering and Bioscience, and her lab team have discovered two new antibodies with promise to treat glaucoma. The antibodies can break down the protein myocilin, which, when it malfunctions, can cause glaucoma.

Lieberman’s group recently published this research in the Proceedings of the National Academy of Sciences: Nexus.